Bachem Holding AG engages in the provision of peptides and oligonucleotides. The company is headquartered in Bubendorf, Basel-Landschaft and currently employs 2,511 full-time employees. The company went IPO on 2001-06-29. The firm focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The firm markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
根据最新的财务报表(Form-10K),Bachem Holding AG 的总资产为 $2,108,净利润为 $148
BCHMF 的关键财务比率是什么?
Bachem Holding AG 的流动比率是 3.24,净利 margin 为 21.29,每股销售为 $9.27。
Bachem Holding AG 的收入按细分市场或地理位置如何划分?
Bachem Holding AG 最大收入来源是 Commercial Active Pharmaceutical Ingredients,在最近的收益报告中收入为 327,002,000。就地区而言, United States 是 Bachem Holding AG 的主要市场,收入为 183,800,000。